# SMIM7

## Overview
SMIM7 (small integral membrane protein 7) is a gene that encodes a transmembrane protein involved in various cellular processes, particularly in the context of cancer biology. The protein product of SMIM7 is characterized by its integration into cellular membranes, where it may play roles in cell signaling and interaction. Research has highlighted its involvement in cancer-related pathways, suggesting that SMIM7 may influence tumor progression and serve as a potential biomarker for prognosis in certain cancers, such as uveal melanoma and liver cancer (Kong2022Immunological). The protein's expression and alternative splicing patterns have been associated with patient survival outcomes, indicating its potential utility in cancer diagnostics and therapy (Denisov2017Clinically). Further studies are required to fully understand the functional mechanisms of SMIM7 and its implications in disease.

## Clinical Significance
SMIM7 (small integral membrane protein 7) has been implicated in various cancer-related processes through alterations in its expression. In uveal melanoma (UM), SMIM7 is part of a prognostic signature based on alternative splicing events that correlate with patient survival. Specifically, the splicing event SMIM7|48185|AT is associated with a low-risk group, which exhibits better overall survival outcomes. This suggests that SMIM7 may play a role in tumor progression and could serve as a potential biomarker for prognosis in UM (Kong2022Immunological).

In liver cancer, SMIM7 has been noted for its role in inhibiting apoptosis, indicating its involvement in cancer cell survival mechanisms (Kong2022Immunological). Additionally, in breast cancer, SMIM7 is significantly downregulated in certain morphological structures of tumors, which may reflect its involvement in the regulation of tumor cell growth and extracellular matrix organization (Denisov2017Clinically).

These findings highlight the potential of SMIM7 as a target for cancer therapy, particularly in the context of immunotherapy, where its expression and splicing patterns could influence immune cell infiltration and tumor immunity (Kong2022Immunological). However, specific diseases directly resulting from mutations in SMIM7 are not well-documented, and further research is needed to fully elucidate its clinical significance.


## References


[1. (Kong2022Immunological) Deqian Kong, Li Li, Huajun Wang, Ke Li, and Guangying Zheng. Immunological significance of survival-related alternative splicing in uveal melanoma. Aging, 14(2):811–825, January 2022. URL: http://dx.doi.org/10.18632/aging.203842, doi:10.18632/aging.203842. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.18632/aging.203842)

[2. (Denisov2017Clinically) Evgeny V. Denisov, Nikolay A. Skryabin, Tatiana S. Gerashchenko, Lubov A. Tashireva, Jochen Wilhelm, Mikhail A. Buldakov, Aleksei A. Sleptcov, Igor N. Lebedev, Sergey V. Vtorushin, Marina V. Zavyalova, Nadezhda V. Cherdyntseva, and Vladimir M. Perelmuter. Clinically relevant morphological structures in breast cancer represent transcriptionally distinct tumor cell populations with varied degrees of epithelial-mesenchymal transition and cd44+cd24- stemness. Oncotarget, 8(37):61163–61180, May 2017. URL: http://dx.doi.org/10.18632/oncotarget.18022, doi:10.18632/oncotarget.18022. This article has 22 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.18022)